JRJosé C. Román-Liñán

José C. Román-Liñán

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


José C. Román-Liñán has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Chemotherapy-Induced Cognitive Impairment (CICI): Pathophysiological Mechanisms and the Rationale for Investigating Ozone Therapy

    by Bernardino Clavo, Gregorio Martínez-Sánchez, Sara E. Cazorla-Rivero, Ángeles Cánovas-Molina, José C. Román-Liñán, Luis Cobiella-Hernández, Sara Ramos-Vega, Carmen G. Pérez-Santana, Juan A. Díaz-Garrido, Mario Federico, et al.

    Chemotherapy-induced cognitive impairment (CICI) is an increasingly recognized complication of cancer treatment, particularly among breast cancer survivors, characterized by persistent difficulties in memory, attention, executive function, and processing speed. This review summarizes current evidence on the clinical phenotype and biological mechanisms of CICI and examines the rationale for investigating medical ozone as a redox-modulating intervention. A translational narrative review was conducted using literature published between 2000 and September 2026, retrieved from PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, complemented by manual reference-list screening. Clinical, preclinical, mechanistic, and evidence-synthesis studies were examined to critically assess the pathophysiology of CICI and the biological rationale for investigating ozone-induced redox modulation. Current evidence points to a multifactorial pathophysiology of CICI and provides a rationale for testing whether controlled redox modulation can influence some of the pathways involved, including activation of endogenous antioxidant and adaptive pathways. Preliminary evidence from chemotherapy-induced peripheral neuropathy and selected neurological or cognitive conditions provides indirect translational support, but does not establish efficacy in CICI. Medical ozone should therefore be considered investigational in this context. The hypothesis should be tested in randomized, sham-controlled trials using validated cognitive outcomes, mechanistic biomarkers, and appropriate oncological safety monitoring to determine whether ozone-induced redox adaptation can produce clinically meaningful cognitive benefit.